Real-world treatment outcomes with halobetasol propionate 0.01%/tazarotene 0.045% lotion in patients with mild-to-moderate plaque psoriasis: A Canadian multicenter retrospective chart review
- Resource Type
- Short Communication
- Source
- In
JAAD International September 2022 8:60-63 - Subject
Research letter - Language
- ISSN
- 2666-3287